TERNTerns Pharmaceuticals, Inc.

Nasdaq ternspharma.com


$ 8.96 $ -0.55 (-5.84 %)    

Friday, 13-Sep-2024 15:59:58 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 8.955
$ 8.94 x 100
$ 8.96 x 345
-- - --
$ 3.26 - $ 11.40
4,498,740
na
630.18M
$ 0.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-27-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-07-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-terns-pharmaceuticals-prices-upsized-15015m-public-offering-of-11919048-at-1050share

Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufactur...

 jmp-securities-maintains-market-outperform-on-terns-pharma-raises-price-target-to-20

JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and raises the price ta...

 terns-pharmaceuticals-oral-glp-1-reaches-phase-1-finish-line-with-encouraging-weight-loss-data-after-one-month

Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and over...

Core News & Articles

PLTR: 8% | Palantir Technologies shares are trading higher amid its addition to the S&P 500 index. TERN: 42% | Terns Pharma...

 jmp-securities-reiterates-market-outperform-on-terns-pharma-maintains-15-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Terns Pharma (NASDAQ:TERN) with a Market Outperform and maintains $15 pric...

 bmo-capital-reiterates-outperform-on-terns-pharma-maintains-19-price-target

BMO Capital analyst Etzer Darout reiterates Terns Pharma (NASDAQ:TERN) with a Outperform and maintains $19 price target.

 terns-pharma-q2-eps-031-beats-034-estimate

Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) ...

 terns-pharmaceuticals-cfo-mark-vignola-to-leave-following-appointment-of-successor-appoints-elona-kogan-as-chief-legal-officer

CEO Amy Burroughs Highlights Kogan's Leadership And Industry Knowledge As Key To Growth; Bryan Yoon To Stay Through Septemb...

 kenneth-griffin-reports-53-passive-stake-in-terns-pharmaceuticals-as-of-july-10

- SEC Filing

 reported-earlier-terns-pharmaceuticals-unveils-preclinical-data-on-obesity-treatment-at-ada-2024

Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical compan...

 hc-wainwright--co-reiterates-neutral-on-terns-pharma-maintains-55-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Terns Pharma (NASDAQ:TERN) with a Neutral and maintains $5.5 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION